2)Lead drug Pro-140-Little to no toxicity than current HIV treatment HAART..Once a week daily shot, could be once a month.NO MORE TOXIC PILLS.
3)Two(2) P-3 data in 2017 A)Adjunct Phase 3 B)Mono-Phase 3-This is where the big money is c)Also testing/Patient injection for graft versus host disease(GvHD) Autoimmune disorders and some cancers
5)BUYOUT IS 100% on the table..why?..with FDA Approval cytodyn is not large enough to take product to market. The science just have to continue being stellar. A)Anthony D. Caracciolo one of those who Formerly responsible for taking Gilead(GILD) from .60 to over $100 now the chairman of cytodyn. http://www.cytodyn.com/about-cytodyn/board-of-directors
6)Gilead is the major player in HIV treatment and 44% of their revenue comes from HIV ..with CYDY stellar results so far one would think GILD will make a move. We could see a buyout war in early/mid 2017.
THERE ARE SO MUCH MORE TO THIS COMPANY- PLEASE DO YOUR DD. BTW NO REVERSE SPLIT. ANY QUESTIONS POP OVER THE CYDY BOARD WE HAVE DOCTORS AND OTHER MAJOR PLAYERS INVESTED AND ACTIVE ON THE BOARD. WE ALL ARE HAPPY TO ANSWER QUESTIONS.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.